Edap Tms (NASDAQ:EDAP - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $20.83 million for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.
Edap Tms Price Performance
Shares of NASDAQ:EDAP traded down $0.09 during trading on Friday, hitting $2.19. 14,130 shares of the company were exchanged, compared to its average volume of 75,296. The business's 50 day moving average is $2.42 and its 200-day moving average is $2.54. The company has a market capitalization of $81.26 million, a P/E ratio of -3.37 and a beta of 0.37. The company has a quick ratio of 1.46, a current ratio of 2.18 and a debt-to-equity ratio of 0.08. Edap Tms has a 1-year low of $2.00 and a 1-year high of $8.50.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on shares of Edap Tms in a research note on Thursday. They issued a "hold" rating on the stock.
Read Our Latest Stock Report on EDAP
Edap Tms Company Profile
(
Get Free Report)
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology.
Further Reading
Before you consider Edap Tms, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edap Tms wasn't on the list.
While Edap Tms currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
